| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2013 | WO2013015535A2 Novel pyrimidine derivative and pharmaceutical composition including same as an active ingredient |
| 01/31/2013 | WO2013015519A1 Antioxidant composition containing isorhamnetin-3-glucoside-7-rhamnoside separated from hippophae rhamnoides leaves as an active ingredient |
| 01/31/2013 | WO2013015429A1 Animal ectoparasite-controlling agent and method for preventing or treating infection in animals caused by parasites by using the controlling agent |
| 01/31/2013 | WO2013015388A1 Ndm inhibitor |
| 01/31/2013 | WO2013015288A1 Lipase activity inhibitor |
| 01/31/2013 | WO2013015152A1 TECHNIQUE FOR CLEAVING OUT PART OF poly(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION |
| 01/31/2013 | WO2013014921A1 Agent for increasing serotonin in brain |
| 01/31/2013 | WO2013014680A1 Method for treatment of pain and inflammation |
| 01/31/2013 | WO2013014660A1 Indane dimers for use in the treatment of autoimmune inflammatory disease |
| 01/31/2013 | WO2013014659A1 Indene derivatives for use in the treatment of inflammatory bowel disease |
| 01/31/2013 | WO2013014629A1 Pharmaceutical compositions comprising pyrrole diones and their use to inhibit angiogenesis |
| 01/31/2013 | WO2013014627A1 Pyrazoline derivatives and their use as selective androgen receptor modulators |
| 01/31/2013 | WO2013014597A1 Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| 01/31/2013 | WO2013014587A1 Heterocyclic amide derivatives as p2x7 receptor antagonists |
| 01/31/2013 | WO2013014569A1 Quinolinyl glucagon receptor modulators |
| 01/31/2013 | WO2013014567A1 Indazoles |
| 01/31/2013 | WO2013014565A1 Compositions and methods for the treatment of metabolic conditions and muscular disorders |
| 01/31/2013 | WO2013014544A1 Method for preparation of composition of piperacillin sodium and tazobactam sodium |
| 01/31/2013 | WO2013014497A1 Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | WO2013014496A1 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | WO2013014480A1 Process for preparation of dronedarone using amide intermediary compound |
| 01/31/2013 | WO2013014476A1 Ear drop compositions and process for producing the ear drop compositions |
| 01/31/2013 | WO2013014473A1 Delivery of an active material |
| 01/31/2013 | WO2013014448A1 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| 01/31/2013 | WO2013014445A1 Derivatives of phenyl (thio) urea deoxythymidine and use thereof as antimalarials |
| 01/31/2013 | WO2013014427A1 Compositions for treatment of skin disorders |
| 01/31/2013 | WO2013014405A2 Methods |
| 01/31/2013 | WO2013014354A1 Novel ceramide analogues, processes for preparing same and uses thereof |
| 01/31/2013 | WO2013014314A2 Derivatives of 5-azolone as calpain inhibitors |
| 01/31/2013 | WO2013014295A1 Process for preparing prasugrel |
| 01/31/2013 | WO2013014274A1 5ht1a antagonist useful for in vivo imaging |
| 01/31/2013 | WO2013014263A1 Levomilnacipran drug for functional rehabilitation after an acute neurological stroke |
| 01/31/2013 | WO2013014255A1 Exosome inhibiting agents and uses thereof |
| 01/31/2013 | WO2013014205A1 Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) aminopropionic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | WO2013014204A2 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | WO2013014185A1 Bicyclic pyrimidone compounds |
| 01/31/2013 | WO2013014170A1 Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| 01/31/2013 | WO2013014162A1 Heterocyclyl pyrimidine analogues as jak inhibitors |
| 01/31/2013 | WO2013014107A1 Semuloparin for improving the survival of patients with cancer |
| 01/31/2013 | WO2013014104A1 Bis-indolic derivatives, their uses in particular as antibacterials |
| 01/31/2013 | WO2013014102A1 Bis-indolic derivatives, a process for preparing the same and their uses as a drug |
| 01/31/2013 | WO2013014074A1 Use of tmprss2 inhibitors as medicaments |
| 01/31/2013 | WO2013014073A1 Phospholipid-detergent conjugates and uses thereof |
| 01/31/2013 | WO2013014060A1 Substituted quinolines and their use as medicaments |
| 01/31/2013 | WO2013014059A1 Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs |
| 01/31/2013 | WO2013014052A1 Composition |
| 01/31/2013 | WO2013014039A1 Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
| 01/31/2013 | WO2013014038A1 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| 01/31/2013 | WO2013013979A1 Use of citrulline and combination compound for improving male fertility |
| 01/31/2013 | WO2013013946A1 Dabigatran-amidoxime acid esters as prodrugs and use thereof as pharmaceuticals |
| 01/31/2013 | WO2013013834A1 New crystalline forms of tulathromycin |
| 01/31/2013 | WO2013013826A1 Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract |
| 01/31/2013 | WO2013013817A1 Substituted heterocyclic aza derivatives |
| 01/31/2013 | WO2013013816A1 Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| 01/31/2013 | WO2013013815A1 Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
| 01/31/2013 | WO2013013798A1 Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof |
| 01/31/2013 | WO2013013776A1 Prolonged release pharmaceutical composition comprising galantamine and method for the preparation thereof |
| 01/31/2013 | WO2013013708A1 Treatment of acute rejection in renal transplant |
| 01/31/2013 | WO2013013657A1 Compressed solid pharmaceutical composition comprising amorphous particulate valsartan as the active ingredient |
| 01/31/2013 | WO2013013640A1 Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof |
| 01/31/2013 | WO2013013614A1 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof |
| 01/31/2013 | WO2013013609A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| 01/31/2013 | WO2013013603A1 Livestock intestinal sustained-release anthelmintic and preparation method therefor |
| 01/31/2013 | WO2013013509A1 Rapid release-slow release osmotic pump preparation of compound methoxyphenamine |
| 01/31/2013 | WO2013013505A1 9-aminomethyl substituted tetracycline compound |
| 01/31/2013 | WO2013013504A1 Tigecycline derivative |
| 01/31/2013 | WO2013013503A1 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| 01/31/2013 | WO2013013490A1 Use of medicament targeting cyslt1 in preparation of drug for prevention or treatment of autoimmune diseases |
| 01/31/2013 | WO2013013417A1 Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds |
| 01/31/2013 | WO2013013404A1 Water soluble camptothecin derivative, pharmaceutical composition and use thereof |
| 01/31/2013 | WO2013013351A1 Immediate release-sustained release osmotic pump perparation of compund methoxyphenamine |
| 01/31/2013 | WO2013013308A1 Spirocyclic molecules as protein kinase inhibitors |
| 01/31/2013 | WO2013013302A1 Synthetic lethality and the treatment of cancer |
| 01/31/2013 | WO2012170098A3 Arbovirus inhibitors and uses thereof |
| 01/31/2013 | WO2012168885A3 Bisacodyl and its analogues as drugs for use in the treatment of cancer |
| 01/31/2013 | WO2012167281A3 Clinical application utilizing genetic data for effective medication management |
| 01/31/2013 | WO2012158913A3 Treating protein folding disorders with small molecule cftr correctors |
| 01/31/2013 | WO2012158856A3 Medicaments and methods for treating cancer |
| 01/31/2013 | WO2012154698A3 Method to improve antiviral activity of nucleotide analogue drugs |
| 01/31/2013 | WO2012149301A3 Tolerogenic synthetic nanocarriers for inducing regulatory b cells |
| 01/31/2013 | WO2012149295A3 Methods of administering anatabine to treat autism spectrum disorders and seizure disorders |
| 01/31/2013 | WO2012148930A3 Oxidative retinal diseases |
| 01/31/2013 | WO2012148929A3 Disorders implicating pufa oxidation |
| 01/31/2013 | WO2012146736A4 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
| 01/31/2013 | WO2012143416A3 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives |
| 01/31/2013 | WO2012142615A3 Auranofin and auranofin analogs useful to treat proliferative disease and disorders |
| 01/31/2013 | WO2012136816A3 Pharmaceutical composition |
| 01/31/2013 | WO2012129562A3 Compounds and methods for inducing chondrogenesis |
| 01/31/2013 | WO2012129066A9 New targets for treatment of er stress |
| 01/31/2013 | WO2012123493A9 Isoxazolidine derivatives |
| 01/31/2013 | WO2012119010A9 Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer |
| 01/31/2013 | WO2012030896A9 Methods for treatment of non-small cell lung cancer |
| 01/31/2013 | WO2012022681A3 Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
| 01/31/2013 | WO2012015946A8 Dispersions of rasagiline citrate |
| 01/31/2013 | WO2011159871A8 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
| 01/31/2013 | WO2011119698A9 Polymorphic forms st-246 and methods of preparation |
| 01/31/2013 | WO2011088181A9 Compounds and methods |
| 01/31/2013 | WO2011083110A3 Use of at least one extract of flowers of camellia japonica alba plena for moisturizing the skin |
| 01/31/2013 | WO2010063862A3 5,6-DIHYDRODIBENZO[b,f][1,4,5]THIADIAZEPINE DERIVATIVES AND THE USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| 01/31/2013 | US20130030237 Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |